In addition, with larger patient cohorts, tumor-specific alterations in genomics, transcriptomics and proteomics can be correlated with clinical prognostic parameters, such as hormone receptor and ERBB2 status, histologic and nuclear grade, Ki67 and clinically available genomic predictive assays such as OncotypeDx DCIS [57]. The gene discussed is ERBB2; the disease is ductal breast carcinoma in situ.